{"id":"W4390793335","doi":"10.2215/cjn.0000000000000384","title":"Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Journal of the American Society of Nephrology","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; University of British Columbia","funders":"Chugai Pharmaceutical; Astellas Pharma; Kyowa Hakko Kirin; National Institutes of Health; Argenx; Omeros Corporation; BioCryst; BeiGene; Alnylam Pharmaceuticals; Alexion Pharmaceuticals; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Sanofi; GlaxoSmithKline; Bayer; AstraZeneca; Vifor Pharma; Pfizer","keywords":"Medicine; Randomized controlled trial; Nephropathy; Internal medicine; Endocrinology; Diabetes mellitus","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002002684,0.002219236,0.003517086,0.0005223341,0.0004928391,0.001227131,0.00112149,0.002609518,0.01151887],"category_scores_gemma":[0.002116944,0.0007915855,0.00191361,0.0004827616,0.000935446,0.001199448,0.0004529721,0.002829138,0.001374077],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007035164,"about_ca_system_score_gemma":0.001529736,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007051152,"about_ca_topic_score_gemma":0.001920384,"domain_scores_codex":[0.9993203,0.0003534211,0.00004075297,0.0001329341,0.00005214672,0.0001005285],"domain_scores_gemma":[0.9990687,0.0002262881,0.000256658,0.00007589546,0.00008812578,0.0002843903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9830062,0.003671073,0.0003277484,0.0009980801,0.0008063785,0.00004505915,0.00003392587,0.0002210349,0.001341927,0.0001336963,0.001244906,0.008169977],"study_design_scores_gemma":[0.9828841,0.01573241,0.0004358145,0.00002930024,0.0001610151,0.00001677701,0.000007162244,0.000169853,0.00007654044,0.00006026928,0.0004207761,0.000006092139],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9424083,0.01683622,0.002195056,0.002982673,0.00199593,0.02264413,0.00437266,0.0005957026,0.005969432],"genre_scores_gemma":[0.9363853,0.008634245,0.005194842,0.004603433,0.001383342,0.03123908,0.003452,0.00005789691,0.009049755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01151887,"threshold_uncertainty_score":0.03853446,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01836121519921078,"score_gpt":0.3560320505741446,"score_spread":0.3376708353749338,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}